Added to YB: 2025-09-25
Pitch date: 2025-09-23
GNFT [neutral]
Genfit S.A.
+63.88%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
Market Cap
EUR 164.0M
Pitch Price
EUR 3.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.42
P/E
-4.23
EV/Sales
1.41
Sector
Biotechnology
Category
growth
Genfit (GNFT France): pipeline reshaped as visibility extends into the next decade
GNFT (quick overview): Discontinued VS-01 program but extends cash runway beyond 2028 via Ipsen milestones/royalty financing. Lead asset G1090N safety/efficacy data by year-end, proof-of-concept 2026. GNS561 cholangiocarcinoma readouts coming soon. Focused oncology/liver pipeline with financial flexibility.
Read full article (2 min)